Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Modulating a complex system carries the possibility of unintended effects that require careful study
Zagon IS, Mclaughlin PJ (2017) Endogenous opioids in the etiology and treatment of multiple sclerosis
PMID 20200426
These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
Trauma Acute Care 2022(3), 12, 2022
US$ 29.59
US$ 27.86
US$ 28.09
US$ 23.17
US$ 22.25
